I am well aware of what you are talking about. You people think NWBO should just skip over several important parts of business development when it comes to the stock-market:
1) NWBO does not have a approved drug anywhere in the world.
2 ) NWBO doesn't have a track record of monetizing their technology in any form or fashion. DCVax is a very complex product to produce...from the logistics to the actual making of the vaccine. I 100% think it works based on the science, but I think the larger question Wall Street wants answered is if it can be scaled, monetized and more importantly ADOPTED by the medical community to drive demand. Can it be? I sure hope so. But the jury isnt out until NWBO gets approval somewhere, starts to mass produce DCVax, then gets medical community "buy-in" to increase demand. These are the Qs that need to be answered, until we have some insight on all this via regular, scheduled quarterly calls that are NOT SHROUDED IN SECRECEY , the SP will continue to lag.
Market Data 
Markets 
AI
